NRX Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

NRXP$2.36-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)


· ·
· · Years ended December 31,
· 2023 · 2022
Operating expenses: · · ·
Research and development	$13,371	$17,027
General and administrative	14,216	27,308
Settlement expense	250	—
Total operating expenses	27,837	44,335
Loss from operations	(27,837)	(44,335)
Other (income) expenses:
Interest income	(494)	(249)
Interest expense	120	—
Change in fair value of convertible note payable	2,707	505
Change in fair value of warrant liabilities	(20)	(255)
Change in fair value of Earnout Cash liability	—	(4,582)
Total other (income) expenses	2,313	(4,581)
Net loss	(30,150)	(39,754)
Deemed dividend - warrants	(9)	—
Net loss attributable to common stockholders	$(30,159)	$(39,754)
Comprehensive loss:
Net loss	(30,150)	(39,754)
Change in fair value of convertible note attributed to credit risk	3	—
Comprehensive loss	$(30,153)	$(39,754)
Net loss per share:
Basic and diluted	$(0.40)	$(0.60)
Weighted average common shares outstanding:
Basic and diluted	75,761,763	65,766,786

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.